COPENHAGEN, DENMARK: Biotech company Adcendo ApS has successfully completed a second Series A extension financing, securing a total of 98 million EUR. The additional 16 million EUR funding was led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors including Novo Holdings, Ysios Capital, RA Capital Management, HealthCap, Gilde Healthcare, and…